Dougherty Initiates Coverage on Phase Forward (PFWD) with a Buy
More News related to PFWD
- Phase Forward (PFWD) Reports Q3 EPS of $0.12, Beats by 2c; Guides Q4
- Phase Forward Reports Third Quarter 2008 Results
- Phase Forward Customer GSK Wins Prestigious Wall Street Journal Technology Innovation Award
- Phase Forward to Host Seventh Annual International Users Conference, October 28-30, San Francisco
- Phase Forward and SGS Life Science Services Continue Collaboration Developing Phase I Trials
More News related to New Coverage
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Dougherty initiates coverage on Phase Forward (Nasdaq: PFWD) with a Buy. Price target $22.50.
Phase Forward Incorporated is a provider of integrated enterprise-level software products, services and hosted solutions for use in the global clinical trial and drug safety monitoring activities of its customers.
Related Categories
New CoverageStocks Mentioned
+0.58Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
